An Open-Label Drug Interaction Study in Healthy Subjects to Evaluate the Effects of Multiple Doses of JNJ55308942 on the Cytochrome P450 CYP3A4, CYP2D6 and CYP2C19 Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol
Latest Information Update: 17 Sep 2021
At a glance
- Drugs JNJ-55308942 (Primary) ; Dextromethorphan; Ethinylestradiol/levonorgestrel; Midazolam; Omeprazole
- Indications Epilepsy; Inflammation; Inflammatory bowel diseases; Mood disorders
- Focus Pharmacokinetics
- Sponsors Janssen-Cilag
Most Recent Events
- 27 Sep 2018 Status changed from recruiting to completed.
- 29 Jun 2018 Status changed from not yet recruiting to recruiting.
- 11 Jun 2018 New trial record